As seen online:
"the National Institute for Health and Care Excellence (NICE) has decided not to offer donanemab on the NHS, citing its “significant cost”."
“In recent weeks, experts have called for more new medicines to be made available on the NHS because this attracts more clinical trials and investment to the UK. Although the UK has a strong history in dementia research, it currently hosts just 7% of global dementia trials and under 3% of participants in phase 3 trials for dementia worldwide live here.”
— from Second Alzheimer’s drug, donanemab, not available on NHS - Alzheimer's Research UK as of 18 December 2025